(Q35588592)

9 August 2017

Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer (English)

1 reference

9 August 2017

1 reference

1 reference

9

I Vergote

1 reference

9 August 2017

H J Huang

1

1 reference

9 August 2017

P Neven

2

1 reference

9 August 2017

M Drijkoningen

3

1 reference

9 August 2017

R Paridaens

4

1 reference

9 August 2017

H Wildiers

5

1 reference

9 August 2017

E Van Limbergen

6

1 reference

9 August 2017

P Berteloot

7

1 reference

9 August 2017

F Amant

8

1 reference

9 August 2017

M R Christiaens

10

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

Journal of Clinical Pathology

9 August 2017

1 reference

9 August 2017

58

1 reference

9 August 2017

6

1 reference

9 August 2017

611-616

1 reference

describes a project that uses

9 August 2017

1 reference

Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

Method for grading breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

Predicting aggressive outcome in T1N0M0 breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

Time to stop progesterone receptor testing in breast cancer management

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

HER-2 testing in breast cancer using parallel tissue-based methods

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

Do we need HER-2/neu testing for all patients with primary breast carcinoma?

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1770673

Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels

26 September 2018

1 reference

12 December 2020

The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer

1 reference

12 December 2020

Oestrogen and progesterone receptor content and the distribution of histological grade in breast cancer.

1 reference

12 December 2020

The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity

1 reference

12 December 2020

Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer

1 reference

12 December 2020

HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer

1 reference

12 December 2020

Immunohistochemical analysis of p53 and HER-2/neu proteins in human tumors

1 reference

12 December 2020

Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: its correlation with sex steroid receptors, cathepsin D and histologic grades

1 reference

12 December 2020

The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases

1 reference

12 December 2020

c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases

1 reference

12 December 2020

Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers

1 reference

12 December 2020

HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study

1 reference

12 December 2020

Identifiers

DOI

10.1136/JCP.2004.022772

1 reference

9 August 2017

1 reference

9 August 2017

1 reference